StockpollyBeta
Get App
Popularity #3,516
IKT · NASDAQ · Biotechnology

Inhibikase Therapeutics (IKT)

Develops IKT-001 as a clinical-stage therapy for pulmonary arterial hypertension.

$2.33
vs last close+0.13 (+5.79%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
5455613151113141821
Research & development333347115861113
212226566778
General & administrative000000000008
Other expenses000000−100100
Operating income−5−4−5−5−6−13−15−11−13−14−18−21
000001111121
Interest income000001111110
Other non-operating income00000−1100−1−2−1
Income before tax−5−4−5−5−6−12−14−10−12−13−16−20
Net income from continuing operations−5−4−5−5−6−12−14−10−12−13−16−20
Net income−5−4−5−5−6−12−14−10−12−13−16−20
EPS, basic−$0.86−$0.68−$0.73−$0.66−$0.65−$0.74−$0.15−$0.11−$0.13−$0.14−$0.10−$0.11
EPS, diluted−$0.86−$0.68−$0.73−$0.66−$0.65−$0.74−$0.15−$0.11−$0.13−$0.14−$0.10−$0.11
Weighted average shares, basic566891690909094172175
Weighted average shares, diluted566891690909094172175
EBITDA−5−4−5−5−6−12−16−11−13−13−16−20
Depreciation & amortization000000000000
EBIT−5−4−5−5−6−12−16−11−13−13−16−20